Peijia Medical (HKG:9996) completed the first patient treatment of the first-in-man clinical trial of ReachTactile robotic-assisted transcatheter aortic valve replacement (TAVR) system on April 2, an April 6 filing with the Hong Kong bourse said.
The procedure was performed by Professor Yan Wang and his team in Xiamen Cardiovascular Hospital of Xiamen University, during which the system was used to implant a TaurusElite(r) transcatheter aortic valve in a patient with severe aortic stenosis.
ReachTactile, the medical device manufacturer's internally developed robotic-assisted TAVR system, offers an innovative solution for TAVR therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.